JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.

Call Us 1 - 866 - 986 - 9598
[email protected]

Sign Up

Login
- My Order
- Return Requests
- Track my Order

Home / Cells / Cell Lines

CD37/CHO Recombinant Cell Line (Low Expression)

SKU : BHC18200296

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Request More Infos

BPS Bioscience

view supplier details

Order Now

Credit card payments now incur a 3% fee.

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Ask Merchant

Request More Infos

Sample Request

Mfr.No.	79607-L
Description	Recombinant clonal stable CHO cell line constitutively expressing full length human CD37 protein, also known as GP52-40; TSPAN26; leukocyte antigen CD37 (Genbank #NM_001774). Surface expression of CD37 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD37 expression, (High, Medium, Low), to mimic different stages of cancer target cells with various CD37 expression levels. Mycoplasma testing: This cell line has been screened using the MycoAlert Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control. Host Species: hamster Supplied as Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Background	CD37 expression is restricted to cells of the immune system, with highest abundance on mature B cells, and lower expression is found on T cells and myeloid cells. CD37 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. It is also expressed in B-cell non-Hodgkin Lymphomas, in chronic lymphocytic leukemia (CLL), and in some cases of cutaneous and peripheral T-cell lymphomas.CAR-37 T cells have demonstrated antigen-specific activation, cytokine production, and cytotoxic activity in models of B- and T-cell lymphomas in vitro and in vivo, including patient-derived xenografts. T cells expressing anti-CD37 CAR have substantial activity against 2 different lymphoid lineages, without evidence of significant T cell fratricide. Furthermore, anti-CD37 CARs have been combined with anti-CD19 CARs to generate dual-specific CAR T cells capable of recognizing CD19 and CD37 alone or in combination. CD37-CAR T cells represent a novel therapeutic agent for the treatment of patients with CD37-expressing lymphoid malignancies.
Application	Useful as CD37-expressing target cells in co-culture assay with CD37-CAR-T cells, for both CD37-specific cell killing assay and cytokine production assay.
Host Cell	CHO
Uniprot	P11049
Species	Human
Shipping Temperature	-80°C (dry ice)
Note	LICENSE DISCLOSURE: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of Biohippo products to your laboratory. Biohippo does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [email protected] for details. Publications using this cell line should reference Biohippo Inc. Warning: Avoid freeze/thaw cycles.

Storage Stability	Store in liquid nitrogen immediately upon receipt.

Reference	1. Scarfò, I. et al. Anti-CD37 chimeric antigen receptor T cells are active against B and Tcell lymphomas. Blood. 2018 Oct; 132(14):1495-1506 2. Witkowska, M. et al. Investigational therapies targeting CD37 for the treatment of Bcelllymphoid malignancies. Expert Opin Investig Drugs. 2018 Feb;27(2):171-177

Product Manual	Datasheet

Have you used this product?

Rate it now..!!

Login to Review

SKU	Supplier No.	Size	Your price	Quantity
BHC18200296	79607-L	2 vials	$7150		Add to Cart

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.

© 2024 Biohippo. All rights reserved.